Novel approaches to profiling hospitals on critical illness mortality
分析医院危重病死亡率的新方法
基本信息
- 批准号:9231482
- 负责人:
- 金额:$ 37.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-04-01 至 2019-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute Lung InjuryAcute respiratory failureAddressAdmission activityAgingAmericanAreaBedsCaringClinicalComplexCritical CareCritical IllnessDataData SetDevelopmentDischarge PlanningsEffectivenessGoalsHealth PolicyHealth care facilityHealth systemHospitalsIncidenceIntensive Care UnitsMeasurementMeasuresMethodsModelingOrganizational ChangeOutcomeOutcome AssessmentOutcome MeasurePatient TransferPatient riskPatient-Focused OutcomesPatientsPennsylvaniaPerformancePoliciesPolicy MakerPopulationProbabilityQuality of CareResearch DesignResearch PersonnelRewardsRiskRoleSepsisServicesStatistical MethodsStatistical ModelsStructural ModelsStructureSyndromeSystemTechniquesTestingTranslatingTranslationsTriageUnited StatesValidationVariantbasecare episodecomparative effectivenessdesigneffectiveness researchhigh riskimprovedimproved outcomeinnovationmortalityneglectnovelnovel strategiespublic health relevancetoolward
项目摘要
DESCRIPTION (provided by applicant): Critical illness represents an extraordinarily high burden on the health system. Between 4 and 7 million Americans are admitted to an intensive care unit (ICU) each year, and the incidence of critical illness syndromes like acute respiratory failure, acute lung injury and sepsis is expected to rise dramatically with the aging of the US population. As a result, the ICU is an increasingly important area for quality improvement initiatives and comparative effectiveness research designed to improve patient outcomes. However, these efforts are limited by the lack of a robust measure of hospital performance for critically ill patients. Existing risk-adjusted mortality measures are limited in several key ways.
First, they only focus on patients admitted to the ICU, neglecting severely ill hospitalized patients who are not admitted, ignoring the role of ICU admission decisions in patient outcomes, and failing to reward hospitals for high-quality care for sick patients on the hospital ward. Second, they exclude patients transferred in from other hospitals and do not account for variation in discharge practices across hospitals, neglecting the role of care transitions in outcomes following critical illness and failing to reward hospitals for high-quality care of comple transfer patients. Third, due to the inherent unreliability of outcome measures they lack sufficien precision to be useful in clinical or health policy decisions. As a result, current risk-adjusted mortality measures may fail to accurately identify high-performing hospitals, hindering both comparative effectiveness research and efforts to translate clinical evidence into practice. This project will address each of these problems through the development and validation of novel methods for measuring hospital-specific risk-adjusted mortality rates for critically ill patients. e base our approach on a conceptual model of critical care quality that emphasizes the entire episode of critical illness, not just the episode of care within an ICU. Using clinical and administrative data from Pennsylvania hospitals, we will apply state-of-the-art Bayesian techniques and an innovative marginal structural modeling approach to create and test hospital- specific critical care mortality rates that account for variation in ICU admission practices and inter- hospital transfers. Then we will develop a new composite measure of critical care mortality rates that combines information about the structure and outcome of care to increase the precision of outcome assessment. Our results will provide clinicians and policy makers with novel measurement tools for assessing critical care performance on a national scale, as well as provide researchers with new measures to test the effectiveness of system-wide clinical and policy innovations designed to improve outcomes for patients with acute respiratory failure and other forms of critical illness.
描述(由申请人提供):危重疾病给卫生系统带来了极大的负担。每年有400万至700万美国人住进重症监护病房(ICU),随着美国人口老龄化,急性呼吸衰竭、急性肺损伤和脓毒症等危重疾病综合征的发生率预计将大幅上升。因此,ICU是旨在改善患者结局的质量改进倡议和比较有效性研究的一个日益重要的领域。然而,由于缺乏对危重患者的医院绩效的强有力的衡量,这些努力受到限制。现有的经风险调整的死亡率指标在几个关键方面受到限制。
首先,他们只关注住进ICU的患者,忽视了没有入院的重症住院患者,忽视了ICU入院决定对患者预后的作用,没有奖励医院在医院病房为患者提供高质量的护理。其次,它们排除了从其他医院转来的患者,也没有考虑到不同医院之间出院做法的差异,忽视了危重疾病后护理过渡在预后中的作用,也没有奖励为复杂转院患者提供高质量护理的医院。第三,由于结果测量本身的不可靠性,它们缺乏足够的精确度,无法在临床或卫生政策决策中发挥作用。因此,目前的风险调整死亡率指标可能无法准确识别表现良好的医院,阻碍了比较有效性研究和将临床证据转化为实践的努力。该项目将通过开发和验证衡量危重患者特定医院风险调整死亡率的新方法来解决这些问题。E我们的方法基于危重护理质量的概念模型,该模型强调危重疾病的整个病程,而不仅仅是ICU内的护理病程。使用来自宾夕法尼亚州医院的临床和管理数据,我们将应用最先进的贝叶斯技术和创新的边际结构建模方法来创建和测试医院特定的危重护理死亡率,这些死亡率考虑到ICU入院实践和医院间转移的差异。然后,我们将开发一种新的重症监护死亡率的综合衡量标准,该衡量标准结合了有关护理结构和结果的信息,以提高结果评估的精确度。我们的结果将为临床医生和政策制定者提供新的衡量工具,用于评估全国范围内的危重护理表现,并为研究人员提供新的衡量标准,以测试旨在改善急性呼吸衰竭和其他形式危重疾病患者预后的全系统临床和政策创新的有效性。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeremy M Kahn其他文献
Leveraging Nurse-Patient Assignments to Improve Outcomes in Intensive Care.
利用护患分配来改善重症监护的结果。
- DOI:
10.4037/ccn2024380 - 发表时间:
2024 - 期刊:
- 影响因子:1.6
- 作者:
K. Riman;Jeremy M Kahn - 通讯作者:
Jeremy M Kahn
Jeremy M Kahn的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeremy M Kahn', 18)}}的其他基金
Organizational strategies for improving evidence-uptake in intensive care
提高重症监护证据吸收的组织策略
- 批准号:
10065517 - 财政年份:2019
- 资助金额:
$ 37.64万 - 项目类别:
Organizational strategies for improving evidence-uptake in intensive care
提高重症监护证据吸收的组织策略
- 批准号:
10540743 - 财政年份:2019
- 资助金额:
$ 37.64万 - 项目类别:
Organizational strategies for improving evidence-uptake in intensive care
提高重症监护证据吸收的组织策略
- 批准号:
10307131 - 财政年份:2019
- 资助金额:
$ 37.64万 - 项目类别:
The effects of state sepsis mandates on hospital mortality, health care utilization, and costs
州脓毒症强制规定对医院死亡率、医疗保健利用率和成本的影响
- 批准号:
9980342 - 财政年份:2017
- 资助金额:
$ 37.64万 - 项目类别:
The effects of state sepsis mandates on hospital mortality, health care utilization, and costs
州脓毒症强制规定对医院死亡率、医疗保健利用率和成本的影响
- 批准号:
9554772 - 财政年份:2017
- 资助金额:
$ 37.64万 - 项目类别:
Novel approaches to profiling hospitals on critical illness mortality
分析医院危重病死亡率的新方法
- 批准号:
9031140 - 财政年份:2015
- 资助金额:
$ 37.64万 - 项目类别:
Organizational Determinants of ICU Telemedicine Effectiveness
ICU 远程医疗有效性的组织决定因素
- 批准号:
9061809 - 财政年份:2014
- 资助金额:
$ 37.64万 - 项目类别:
Organizational Determinants of ICU Telemedicine Effectiveness
ICU 远程医疗有效性的组织决定因素
- 批准号:
9277535 - 财政年份:2014
- 资助金额:
$ 37.64万 - 项目类别:
Organizational Determinants of ICU Telemedicine Effectiveness
ICU 远程医疗有效性的组织决定因素
- 批准号:
8753271 - 财政年份:2014
- 资助金额:
$ 37.64万 - 项目类别:
The role of long term acute care hospitals in prolonged mechanical ventilation
长期急症护理医院在延长机械通气方面的作用
- 批准号:
8135941 - 财政年份:2009
- 资助金额:
$ 37.64万 - 项目类别:
相似海外基金
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
- 批准号:
10648387 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
- 批准号:
10720687 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
- 批准号:
10719249 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
- 批准号:
10591804 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
- 批准号:
10741574 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
- 批准号:
23K07651 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
- 批准号:
10679944 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
- 批准号:
10575258 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
- 批准号:
10701207 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Identification of novel phenotypes of acute lung injury using multimodal longitudinal data
使用多模态纵向数据识别急性肺损伤的新表型
- 批准号:
MR/Y000404/1 - 财政年份:2023
- 资助金额:
$ 37.64万 - 项目类别:
Fellowship